GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmena SA (WAR:PHR) » Definitions » Price-to-Owner-Earnings

Pharmena (WAR:PHR) Price-to-Owner-Earnings : 2.18 (As of Jun. 03, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Pharmena Price-to-Owner-Earnings?

As of today (2024-06-03), Pharmena's share price is zł5.92. Pharmena's Owner Earnings per Share (TTM) ended in Mar. 2024 was zł2.72. It's Price-to-Owner-Earnings for today is 2.18.


The historical rank and industry rank for Pharmena's Price-to-Owner-Earnings or its related term are showing as below:

WAR:PHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.41   Med: 61.86   Max: 3300
Current: 2.17

During the past 13 years, the highest Price-to-Owner-Earnings of Pharmena was 3300.00. The lowest was 1.41. And the median was 61.86.


WAR:PHR's Price-to-Owner-Earnings is ranked better than
97.56% of 164 companies
in the Biotechnology industry
Industry Median: 33.035 vs WAR:PHR: 2.17

As of today (2024-06-03), Pharmena's share price is zł5.92. Pharmena's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was zł2.63. Therefore, Pharmena's PE Ratio for today is 2.25.

As of today (2024-06-03), Pharmena's share price is zł5.92. Pharmena's EPS without NRI for the trailing twelve months (TTM) ended in was zł-0.47. Therefore, Pharmena's PE Ratio without NRI for today is At Loss.

During the past 13 years, Pharmena's highest PE Ratio without NRI was 516.25. The lowest was 0.00. And the median was 186.35.


Pharmena Price-to-Owner-Earnings Historical Data

The historical data trend for Pharmena's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmena Price-to-Owner-Earnings Chart

Pharmena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 76.71 2.52

Pharmena Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.90 1.86 2.11 2.52 3.06

Competitive Comparison of Pharmena's Price-to-Owner-Earnings

For the Biotechnology subindustry, Pharmena's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmena's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmena's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pharmena's Price-to-Owner-Earnings falls into.



Pharmena Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pharmena's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=5.92/2.72
=2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmena  (WAR:PHR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pharmena Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pharmena's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmena (WAR:PHR) Business Description

Traded in Other Exchanges
N/A
Address
Ulica Wolczanska 178, Lodz, POL, 90-530
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.